Tulsi Therapeutics, a biotech startup from Hyderabad, has reversed chronic liver failure in animal trials using Tulsi-28X, a first-in-class stem cell–exosome therapy. The innovation showed 100% survival and fibrosis reversal, setting the stage for human clinical trials.
The initiative is aimed at supporting Centres of Excellence (CoEs) across India and ASPIRE-BioNEST is one of the four centres selected for the collaboration.
ASPIRE BioNEST incubated startup SCIINV Biosciences AI/ML digital diagnostic platform AMRx at the University of Hyderabad (UoH) has been included in the Coffee Table Book which lists the top 200 AI first movers who are leveraging the power of AI to transform their businesses
Dr. Sairam Reddy raised concerns over the increasing levels of pesticides and heavy metals in fruits and vegetables and advocated for urban farming as a sustainable solution.
Type 2 diabetes is the world’s most prevalent chronic disease and often described as the silent killer. There are many drugs available for the disease yet patients are not able to maintain healthy levels of blood glucose.
Hyderabad: Research by ReaGene Innovations Private Limited, a startup incubated at the ASPIRE-BioNEST, and INDRAS Private Limited suggests that an anti-diabetic drug Ertugliflozin, can be repurposed to treat Covid-19. According to the findings, the repurposed drug binds effectively to the receptor binding domain of the spike protein of Covid-19 and also displayed significant anti-inflammatory and […]
The first result offering a safe, ready-to-use and cost-effective solution for Covid-19 treatment, Ertugliflozin is an FDA approved drug for type-2 diabetes.
A graduated startup company of ASPIRE-BioNEST incubator at UoH was identified as an emerging start-up company by an independent jury panel of ChemTech- Biopharma conference 2021
ASPIRE BioNEST, formed as a knowledge-based incubator, nurtures innovation and entrepreneurship in scaling technologies of Agriculture, Biotechnology, Healthcare, Pharmaceutical, and allied areas
